Key result
DAPT ties to lower early neurological deterioration risk only in large-artery stroke, differing by etiology.
Why the study?
Little is known about neurological worsening during the first 24 hours after stroke admission, and the relationship between DAPT and very early neurological deterioration across different stroke etiologies remains unclear.
Does newly initiated dual antiplatelet therapy reduce very early neurological deterioration in adults with non-cardioembolic acute ischemic stroke compared to single antiplatelet therapy?
Cohort (n=1,207)
No
Does newly initiated dual antiplatelet therapy reduce very early neurological deterioration in adults with non-cardioembolic acute ischemic stroke compared to single antiplatelet therapy?
Answers are grounded in this paper and cite their sources.
DAPT may be associated with a lower risk of very early neurological deterioration in LAA stroke but not in non-LAA stroke, highlighting the need for etiology-specific antiplatelet strategies.
Introduction – Early neurological deterioration after ischemic stroke is associated with worse clinical outcome, yet little is known about the frequency and determinants of neurological worsening during the first 24 hours after admission. Dual antiplatelet therapy (DAPT) is recommended early after minor non-cardioembolic stroke to reduce recurrent ischemic events, but its relationship with very early deterioration (vEND) and potential differences across stroke etiologies remain unclear. Patients and methods – We conducted a retrospective single-center cohort study including consecutive adults with non-cardioembolic ischemic stroke admitted to a Swiss tertiary stroke center between 2014 and 2023. vEND was defined as neurological worsening within 24 hours using two thresholds (NIHSS increase ≥4 points [primary] and ≥2 points [secondary]). Patients were categorized according to antiplatelet strategy (newly initiated DAPT vs single antiplatelet therapy [SAPT]) and stroke etiology (large artery atherosclerosis [LAA] vs non-LAA). Associations between antiplatelet therapy and vEND were analyzed using propensity score-weighted logistic regression with stabilized inverse probability of treatment weights and doubly robust adjustment. Adjusted predicted probabilities and risk differences were estimated using marginal standardization. Results – Among 1,207 patients with non-cardioembolic stroke, vEND occurred in 22.2% using the primary definition (NIHSS increase ≥4 points) and in 25.8% using the secondary definition (NIHSS increase ≥2 points). vEND was more frequent in non-LAA than LAA stroke under both definitions (23.5% vs 17.6% and 26.4% vs 23.7%, respectively). Patients with LAA were more likely to receive DAPT than those without LAA (33.6% vs 14.4%, p<0.001). After weighting and adjustment, the association between antiplatelet therapy and vEND differed by stroke etiology (pinteraction<0.001 [primary] and pinteraction=0.007 [secondary]). In LAA stroke, DAPT was associated with a numerically lower risk of vEND compared with SAPT (adjusted risk difference [primary definition]: -7.3%, 95% CI -16.9% to 2.3%). In contrast, among non-LAA stroke patients, DAPT was associated with a higher vEND risk (adjusted risk difference [primary definition]: 16.6%, 95% CI 7.1% to 26.1%). Similar patterns were observed using the secondary vEND definition (NIHSS increase of ≥2 points). Discussion and conclusion – Very early neurological deterioration within the first 24 hours after non-cardioembolic stroke is common and occurs more frequently in non-LAA stroke. The association between DAPT and vEND appears to differ by stroke etiology. A lower risk was observed in LAA stroke, whereas the higher risk seen in non-LAA stroke likely reflects confounding by indication. Prospective studies are needed to determine whether intensified platelet inhibition may reduce very early deterioration in LAA-related stroke.
No takes yet. Share an insight, caveat, or question.
Pereppadan et al. (2026) conducted a cohort in Non-cardioembolic ischemic stroke (n=1,207). Dual antiplatelet therapy (DAPT) vs. Single antiplatelet therapy (SAPT) was evaluated on Very early neurological deterioration (vEND) defined as NIHSS increase ≥4 points within 24 hours (Adjusted risk difference -7.3% (LAA) and 16.6% (non-LAA), p=<0.001). In patients with non-cardioembolic stroke, the association between DAPT and very early neurological deterioration differed by etiology, with a numerically lower risk in LAA stroke and a higher risk in non-LAA stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: